Recent YSCC Discoveries
Highlights from the 2023 American Society of Hematology Annual Meeting
- March 19, 2024
A new study offers insight into why some groups of patients with asthma may not respond to certain medications.
- March 19, 2024
During a Women’s History Month reception at the White House on Monday, President Biden announced an executive order focused on women’s health research. Carolyn Mazure, PhD, of YSM, now a member of his team, made substantial contributions to it.
- March 15, 2024
Katerina Politi, PhD, Professor of Pathology; Co-Leader, Cancer Signaling Networks; and Scientific Director for the Center for Thoracic Cancers, is one of five individuals newly elected to the American Association for Cancer Research (AACR) Board of Directors.
- March 12, 2024
The newly announced election brings the number of AAP members from Yale to 53.
- March 11, 2024
Janice Crabtree has been honored with the 2024 Donna Wachter Clerkship Coordinator Award through the Association of Professors of Gynecology and Obstetrics [APGO].
- March 11, 2024
The National Institutes of Health (NIH) recently awarded Yibing Qyang, PhD, and his colleagues a $2+ million R01 grant to support research to create an artificial blood vessel that can grow, pump, and resist infection and clotting.
- March 11, 2024
As a part of our “Meet Yale Internal Medicine” series, today’s feature is on Romina Fiorotto, PhD, assistant professor (digestive diseases and pathology).
- February 28, 2024
The Marcus Foundation has awarded $13.2 million to Yale School of Medicine, to support a clinical trial that could mark a first step toward a preventive treatment for Parkinson's disease.
- February 28, 2024
Yale Cancer Center has a long history of breakthrough cancer research and is perhaps best known as the institution where cancer chemotherapy and the entire field of cancer drug development was discovered and the very first cancer drug was administered in 1942. Dr. William Gardner's studies on steroid hormones and their role in experimental carcinogenesis added another dimension to our understanding of malignant disease. The first FDA approved selective immunotherapy treatment for any type of cancer, Transimmunization, was also developed at Yale under the direction of Dr. Richard Edelson.